Technical Analysis for CARM - Carisma Therapeutics, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 1.63 | -4.68% | -0.08 |
CARM closed down 4.68 percent on Friday, April 19, 2024, on 1.43 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: May 9
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New 52 Week Closing Low | Bearish | 0.00% | |
New 52 Week Low | Weakness | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Boomer Sell Setup | Bearish Swing Setup | -4.68% | |
Bullish Engulfing | Bullish | -4.68% | |
NR7 | Range Contraction | -4.68% | |
Inside Day | Range Contraction | -4.68% | |
Wide Bands | Range Expansion | -4.68% | |
Oversold Stochastic | Weakness | -4.68% |
Alert | Time |
---|---|
Down 5% | about 14 hours ago |
Down 10% | about 14 hours ago |
Down 1 ATR | about 14 hours ago |
Down 3% | about 15 hours ago |
Boomer Sell Entry | about 15 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
Carisma Therapeutics Inc. is a biopharmaceutical company dedicated to developing a differentiated and proprietary cell therapy platform focused on engineered macrophages, cells that play a crucial role in both the innate and adaptive immune response. The first applications of the platform, developed in collaboration with the University of Pennsylvania*, are autologous chimeric antigen receptor (CAR)-macrophages for the treatment of solid tumors.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Solid Tumors Immune System Cell Therapy Chimeric Antigen Receptor T Cell Natural Killer Cell Antigen Induced Stem Cells
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Solid Tumors Immune System Cell Therapy Chimeric Antigen Receptor T Cell Natural Killer Cell Antigen Induced Stem Cells
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 9.7662 |
52 Week Low | 1.53 |
Average Volume | 179,145 |
200-Day Moving Average | 3.72 |
50-Day Moving Average | 2.24 |
20-Day Moving Average | 1.99 |
10-Day Moving Average | 1.83 |
Average True Range | 0.18 |
RSI (14) | 30.56 |
ADX | 31.76 |
+DI | 9.15 |
-DI | 28.54 |
Chandelier Exit (Long, 3 ATRs) | 2.13 |
Chandelier Exit (Short, 3 ATRs) | 2.06 |
Upper Bollinger Bands | 2.49 |
Lower Bollinger Band | 1.50 |
Percent B (%b) | 0.13 |
BandWidth | 49.35 |
MACD Line | -0.17 |
MACD Signal Line | -0.15 |
MACD Histogram | -0.029 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.93 | ||||
Resistance 3 (R3) | 1.93 | 1.83 | 1.88 | ||
Resistance 2 (R2) | 1.83 | 1.75 | 1.83 | 1.86 | |
Resistance 1 (R1) | 1.73 | 1.71 | 1.68 | 1.73 | 1.85 |
Pivot Point | 1.63 | 1.63 | 1.61 | 1.63 | 1.63 |
Support 1 (S1) | 1.53 | 1.55 | 1.48 | 1.53 | 1.41 |
Support 2 (S2) | 1.43 | 1.51 | 1.43 | 1.40 | |
Support 3 (S3) | 1.33 | 1.43 | 1.38 | ||
Support 4 (S4) | 1.33 |